Patents

Columbia University receives patent for mda-7 apoptosis induction

Published in Gene Therapy Weekly, August 1st, 2002

Introgen Therapeutics, Inc., (INGN) and the Trustees of Columbia University announced that the United States Patent and Trademark Office has issued to the Trustees of Columbia University U.S. Patent No. 6,355,622 entitled "Use of a melanoma differentiation associated gene (mda-7) for inducing apoptosis of a tumor cell" listing Columbia scientist Paul Fisher as inventor.

The patent relates to treatment methods employing the mda-7 tumor suppressor gene. The mda-7 gene is the subject of Introgen's gene therapeutic INGN 241 currently being tested in a phase 1 clinical trial for the treatment of solid tumors in cancer patients. Clinical data from this trial will be...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-08-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry